Article info

PDF

Original Article
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

Authors

  1. Correspondence to Maarten Arends, Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam 1100 DD, The Netherlands; m.arends{at}amc.uva.nl
View Full Text

Citation

Arends M, Biegstraaten M, Wanner C, et al
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

Publication history

  • Received June 12, 2017
  • Revised January 7, 2018
  • Accepted January 12, 2018
  • First published February 7, 2018.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.